top of page
Conflict of interest statements

​

The authors received an honorarium from Apobiologix for their participation as ambassadors at ESMO Immuno-Oncology 2025 and their contributions to the development of this white paper.

Dr. Singh has been an advisor and/or received an honorarium from Novartis, Ipsen, and Boehringer Ingelheim.

Dr. Chua received honoraria for ad hoc Advisory Board meetings for Roche, AbbVie, BeOne Medicine, Pfizer, and Merck and speaker honorarium from Merck.

Dr. Marton stated that she has no additional disclosures to report in association with the contents of this article.

Dr. Smoragiewicz has received honoraria from Merck, Bayer, Janssen, McKesson, Knight Therapeutics, Ipsen, EMD Serono, Eisai, Astellas, Apobiologix, and Regeneron. 

Dr. Faour stated that she has no additional disclosures to report in association with the contents of this article.

SNELL Medical Communication acknowledges that it has received arm’s length educational funding from Apobiologix to support the development and distribution of this educational publication. The acceptance of funding was contingent upon the sponsors’ adherence to SNELL Medical Communication’s policy designed to preserve the educational integrity of the publication. This policy ensures that the authors will at all times exercise unrestricted, rigorous, scientific independence free of interference from any other party. 

​

©2026 Published by SNELL Medical Communication Inc. through arm’s length educational funding from Apobiologix. All rights reserved. The opinions expressed in this publication do not necessarily reflect those of the publisher or its educational sponsor, but rather are those of the authors based on the available scientific literature. The administration of any therapies discussed or referred to should always be consistent with the recognized prescribing information as required in Canada. SNELL Medical Communication Inc. is committed to the development of superior Continuing Medical Education.

bottom of page